SCHEMBL10045301

SCHEMBL10045301

Bc1ccc(-c2nc3ccccc3s2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.69
NPC1 O15118 7/20 0.69
APP P05067 6/20 0.69
KDM4E B2RXH2 4/20 0.69
MAPT P10636 3/20 0.69
GLA P06280 2/20 0.69
GAA P10253 2/20 0.69
MMP9 P14780 2/20 0.69
MMP8 P22894 2/20 0.69
ALDH1A1 P00352 2/20 0.69
LMNA P02545 1/20 0.69
KMT2A Q03164 4/20 0.63
MEN1 O00255 3/20 0.63
PKM P14618 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
PAX8 Q06710 1/20 0.63
NOD2 Q9HC29 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
TNF P01375 1/20 0.63
NOD1 Q9Y239 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29474819 0.90 RAB9A (0.81) RAB9ANPC1APPKDM4EMAPT
SCHEMBL366824 0.90 RAB9A (0.81) RAB9ANPC1APPKDM4EMAPT
SCHEMBL24295138 0.88 RAB9A (0.79) RAB9ANPC1APPKDM4EMAPT
SCHEMBL754574 0.85 RAB9A (0.73) RAB9ANPC1APPKDM4EMAPT
2-Phenylbenzo[D]Thiazole SCHEMBL30988131 0.84 RAB9A (0.75) RAB9ANPC1APPKDM4EMAPT
2-Phenylbenzo[D]Thiazole SCHEMBL94005 0.84 RAB9A (0.75) RAB9ANPC1APPKDM4EMAPT
SCHEMBL13894027 0.84 KDM4E (0.59) RAB9ANPC1APPKDM4EMAPT
SCHEMBL24332358 0.83 APP (0.71) RAB9ANPC1APPKDM4EMAPT
2-Phenylbenzo[D]Thiazole SCHEMBL2453217 0.82 RAB9A (0.72) RAB9ANPC1APPKDM4EMAPT
2-Phenylbenzo[D]Thiazole SCHEMBL29986751 0.82 RAB9A (0.72) RAB9ANPC1APPKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021230512-A1 BENZAZOLE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME 주식회사 랩토 2021-11-18 WO disclosed
EP-2818462-B1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMISCENT ELEMENT CONTAINING THESE AS COMPONENT TOSOH CORP (JP) 2017-11-08 EP disclosed
US-8927121-B2 Emissive aryl-heteroaryl compounds NITTO DENKO CORPORATION (JP) 2015-01-06 US disclosed
US-8927121-B2 Emissive aryl-heteroaryl compounds NITTO DENKO CORPORATION (JP) 2015-01-06 US disclosed
US-8771845-B2 2014-07-08 US disclosed
US-8771845-B2 2014-07-08 US disclosed
US-20130284907-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2013-10-31 US disclosed
US-20130284907-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2013-10-31 US disclosed
US-8120022-B2 Light emitting device material and light emitting device TORAY INDUSTRIES, INC. (JP) 2012-02-21 US disclosed
US-8120022-B2 Light emitting device material and light emitting device TORAY INDUSTRIES, INC. (JP) 2012-02-21 US disclosed
WO-2011008560-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2011-01-20 WO disclosed
US-20100187520-A1 LIGHT EMITTING DEVICE MATERIAL AND LIGHT EMITTING DEVICE TORAY INDUSTRIES, INC. (JP) 2010-07-29 US disclosed
US-20100187520-A1 LIGHT EMITTING DEVICE MATERIAL AND LIGHT EMITTING DEVICE TORAY INDUSTRIES, INC. (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100187520-A1 LIGHT EMITTING DEVICE MATERIAL AND LIGHT EMITTING DEVICE LEF1, CRY1, SOD1 RAB9A 425/4885NPC1 2107/4885APP 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.